Other proposed mechanisms suggest that empagliflozin enhanced fat utilization and browning, attenuated obesity-induced inflammation, and suppressed weight gain and insulin resistance by polarizing M2 macrophages and lowering plasma tumor necrosis factor-alpha (TNFα) levels in WAT and the liver [74,78]. Here, TNF is linked to obesity due to melanocortin 4 receptor deficiency.